We are currently focusing our efforts on commercializing Proclarix. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (“PSA”) test. The PSA test is a well-established prostate specific marker that measures the concentration of PSA molecules in a blood sample.
Approved · ActiveModality: oral combination (finasteride and tadalafil)
Indications
benign prostatic hyperplasia (BPH)(Approved)
Status note FDA-approved once-daily pill combining finasteride and tadalafil for BPH; acquired April 2023.
Proclarix
Approved · ActiveModality: lab developed test (LDT)
Target Prostate cancer biomarkers (blood-based IVD)
Partnerships LabCorp: license agreement (marketed in US as an LDT)
Indications
Prostate cancer diagnosis (risk assessment of clinically significant prostate cancer)(Approved)
Status note Marketed in the US as a lab developed test through the LabCorp license agreement; excerpts describe company efforts to commercialize Proclarix. The company's earlier vaccine candidates are described as 'now halted' (unnamed).
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.